Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: A focus on toxicogenomics

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 11, 2010, Pages 1347-1362

  Akhtar, Saghir ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

drug delivery carriers; nanomedicine; nanoparticles; PAMAM; polyethyleneimine; polypropylenimine; RNAi; toxicology

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTIINFECTIVE AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHAPERONIN; DENDRIMER; DOXORUBICIN; LIPID; LIPOFECTAMINE; LIPOFECTIN; LIPOSOME; NANOPARTICLE; OLIGOFECTAMINE; OLIGONUCLEOTIDE; POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYMER; POLYPROPYLENIMINE; REPLICATION FACTOR A; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

CELL MIGRATION; CYTOTOXICITY; DRUG FORMULATION; DRUG STABILITY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE TRANSFER; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; NANOMEDICINE; PREDICTION; REVIEW; RNA INTERFERENCE;

ANIMALS; CATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE SILENCING; HUMANS; NANOPARTICLES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOXICOGENETICS;

EID: 77958454568     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.518611     Document Type: Review

References (104)

1. Poma A, Di Giorgio ML. Toxicogenomics to improve comprehension of the mechanisms underlying responses of in vitro and in vivo systems to nanomaterials: a review. Curr Genomics 2008;9(8):571-585
2. Godin B, Sakamoto JH, Serda RE, et al. Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol 2010; In press
3. Riehemann K, Schneider SW, Luger TA, et al. Nanomedicine - challenge and perspectives. Agnew Chem Int Ed Engl 2009;48:872-897
4. Teli MK, Mutalik S, Rajanikant GK. Nanotechnology and nanomedicine: going small means aiming Big. Curr Pharm Design 2010; In press
5. Akhtar S, Benter IF. Non-viral delivery of synthetic siRNAs in vivo. J Clinical Invest 2007a;117(12):3623-3632
6. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8(2):129-138
7. Costanotto D, Rossi JR. The promises and pitfalls of RNA-interference- based therapeutics. Nature 2009;457(7228):426-433
8. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010;50:259-293
9. Akhtar S, Hughes MD, Khan A, et al. The delivery of antisense therapeutics. Adv Drug Deliv Rev 2000;44(1):3-21
10. Beale G, Hollins AJ, Benboubetra M, et al. Gene silencing nucleic acids designed by scanning arrays: anti-EGFR activity of siRNA, ribozyme and DNA enzymes targeting a single hybridization-accessibleregion using the same delivery system. J Drug Target 2003;11(7):449-456
11. Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: potentials and limits of nanosystems. Nanomedicine 2009;5(1):8-20
12. Kurreck J. RNA interference: from basic research to therapeutic applications. Angew Chem Int Ed Engl 2009;48(8):1378-1398
13. Martinez J, Patkaniowska A, Urlaub H, et al. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002;110:563-574
14. Liu Q, Paroo Z. Biochemical principles of small RNA pathways. Annu Rev Biochem 2010; In press
15. Martin SE, Caplen NJ. Applications of RNA interference in mammalian systems. Annu Rev Genomics Hum Genet 2007;8:81-108
16. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-811
17. Schroeder A, Levins CG, Cortez C, et al. Lipid-based nanotherapeutics for siRNA delivery. J Intern Med 2010;267(1):9-21
18. Aouadi M, Tesz GJ, Nicoloro SM, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009;458(7242):1180- 1184
19. Akhtar S. Oral delivery of siRNA and antisense oligonucelotides. J Drug Target 2009;17(7):491-495
20. Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010;9(1):57-67
21. Jackson AL, Bartz SR, Schelter J, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003;21:635-637
22. Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003;5(9):834-839
23. Marques JT, Williams BR. Activation of the mammalian immune system by siRNAs. Nat Biotechnol 2005;23:1399-1405
24. Robbins M, Judge A, Maclachlan I. siRNA and innate immunity. Oligonucleotides 2009;19(2):89-102
25. Sioud M. Deciphering the code of innate immunity recognition of siRNAs. Methods Mol Biol 2009;487:41-59
26. Lin X, Ruan X, Anderson MG, et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation, Nucleic Acids Res 2005;33:4527-4535
27. Birmingham A, Anderson EM, Reynolds A, et al. 3¢ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 2006;3:199-204
28. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006;441:537-541
29. Akhtar S, Benter I. Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev 2007b;59(2-3):164-182
30. Gonzalez Ferreiro M, Tillman LG, Hardee G, et al. Alginate/poly-L-lysine microparticles for the intestinal delivery of antisense oligonucleotides. Pharm Res 2002;19(6):755-764
31. Khan A, Benboubetra M, Sayyed PZ, et al. Sustained polymeric delivery of gene silencing antisense ODNs, siRNA, DNAzymes and ribozymes: in vitro and in vivo studies. J Drug Target 2004;12(6):393-404
32. Woodrow KA, Cu Y, Booth CJ, et al. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater 2009;8(6):526-533
33. Bumcrot D, Manoharan M, Koteliansky V, et al. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006;2(12):711-719
34. Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces off-target transcript silencing. RNA 2006;12:1197-1205
35. Schwarz DS, Hutvagner G, Du T, et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003;115(2):199-208
36. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003;115(2):209-16. Erratum in: Cell 2003;115(4):505
37. van de Water FM, Boerman OC, Wouterse AC, et al. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos 2006;34(8):1393-1397
38. Kawakami S, Hashida M. Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 2007;22(3):142-151
39. Huang L, Sullenger B, Juliano RL. The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides. J Drug Targeting 2010; In press
40. Juliano R, Alam MR, Dixit V, et al. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008;36(12):4158-4171
41. Akhtar S, Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol Sci 1997;18(1):12-18
42. Braasch DA, Paroo Z, Constantinescu A, et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004;14(5):1139-1143
43. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharm 2009;6(3):659-668
44. Feinberg EH, Hunter CP. Transport of dsRNA into cells by the transmembrane protein SID-1. Science 2003;301(5639):1545-1547
45. Beltinger C, Saragovi HU, Smith RM, et al. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 1995;95(4):1814-1823
46. Akhtar S, Juliano RL. Cellular uptake and intracellular fate of antisense oligonucleotides. Trends in Cell Biology 1992;2:139-144
47. Li W, Szoka FC Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007;24(3):438-449
48. Heath F, Haria P, Alexander C. Varying polymer architecture to deliver drugs. AAPS J 2007;9(2):E235-40
49. Grayson SM, Godbey WT. The role of macromolecular architecture in passively targeted polymeric carriers for drug and gene delivery. J Drug Target 2008;16(5):329-356
50. Decuzzi P, Godin B, Tanaka T, et al. Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release 2010;141(3):320-327
51. Ambrose EJ, Easty DM, Jones PC. "Specific reactions of polyelectrolytes with the surfaces of normal and tumour cells". Brit J Cancer 1958;12:439-447
52. Akhtar S. Non-viral vectors for gene therapy: Beyond delivery. Gene Therapy 2006;13:739-740
53. Kabanov AV, Batrakova EV, Sriadibhatla S, et al. Polymer genomics: shifting the gene and drug delivery paradigms. J Control Release 2005;101(1-3):259-271
54. Kabanov AV. Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv Drug Deliv Rev 2006;58(15):1597-1621
55. Khor TO, Ibrahim S, Kong AN. Toxicogenomics in drug discovery and drug development: potential applications and future challenges. Pharm Res 2006;23(8):1659-1664
56. Fielden MR, Kolaja KL. The state-of-the-art in predictive toxicogenomics. Curr Opin Drug Discov Dev 2006;9(1):84-91
57. Audouy SA, de Leij LF, Hoekstra D, et al. In vivo characteristics of cationic liposomes as delivery vectors for gene therapy. Pharm Res 2002;19:1599-1605
58. Sorensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003;327:761-766
59. Verma UN, Surabhi RM, Schmaltieg A, et al. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-1300
60. Arnold AS, Tang YL, Qian K, et al. Specific beta1-adrenergic receptor silencing with small interfering RNA lowers high blood pressure and improves cardiac function in myocardial ischemia. J Hypertens 2007;25(1):197-205
61. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006;441(7089):111-114
62. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010;28(2):172-176
63. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432(7014):173-178
64. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal ebola virus challenge isconferred by RNA interference. J Infect Dis 2006;193(12):1650-1657
65. Pirollo KF, Rait A, Zhou Q, et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007;67(7):2938-2943
66. Kizelsztein P, Ovadia H, Garbuzenko O, et al. Pegylated nanoliposomes remote-loaded with the antioxidant tempamine ameliorate experimental autoimmune encephalomyelitis. J Neuroimmunol 2009;213(1-2):20-25
67. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci 2009;30(11):592-599
68. Semple SC, Harasym TO, Clow KA, et al. Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid. J Pharmacol Exp Ther 2005;312(3):1020-1026
69. Omidi Y, Hollins AJ, Benboubetra M, et al. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gen expression changes in human epithelial cells. J Drug Target 2003;11(6):311-323
70. Omidi Y, Barar J, Heidari HR, et al. Microarray analysis of the toxicogenomics and the genotoxic potential of a cationic lipid-based gene delivery nanosystem in human alveolar epithelial A549 cells. Toxicol Mech Methods 2008;18(4):369-378
71. Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci USA 1989;86(16):6077-6081
72. Fedorov Y, King A, Anderson E, et al. Different delivery methods-different expression profiles. Nat Methods 2005;2:241
73. Omidi Y, Hollins AJ, Drayton RM, et al. Polypropylenimine dendrimer-induced gene expression changes: the effect of complexation with DNA, dendrimer generation and cell type. J Drug Target 2005;13(7):431-443
74. Gilmore IR, Fox SP, Hollins AJ, et al. The design and exogenous delivery of siRNA for post-transcriptional gene silencing. J Drug Target 2004;12(6):315-340
75. Gilmore IR, Fox SP, Hollins AJ, et al. Delivery strategies for siRNA-mediated gene silencing. Curr Drug Deliv 2006;3(2):147-155
76. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995;92(16):7297-7301
77. Kichler A. Gene transfer with modified polyethylenimines. J Gene Med 2004;6(Suppl 1):S3-10
78. Kircheis R, Wightman L, Wagner E. Design and gene delivery activity of modified polyethylenimines. Adv Drug Deliv Rev 2001;53(3):341-358
79. Grayson AC, Doody AM, Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm Res 2006;23(8):1868-1876
80. Ge Q, Filip L, Bai A, et al. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 2004;101(23):8676-8681
81. Urban-Klein B, Werth S, Abuharbeid S, et al. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005;12(5):461-466
82. Hobel S, Koburger I, John M, et al. Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med 2010;12(3):287-300
83. Merkel OM, Beyerle A, Librizzi D, et al. Nonviral siRNA delivery to the lung: investigation of PEG-PEI polyplexes and their in vivo performance. Mol Pharm 2009;6(4):1246-1260
84. Jere D, Jiang HL, Arote R, et al. Degradable polyethylenimines as DNA and small interfering RNA carriers. Expert Opin Drug Deliv 2009;6(8):827-834
85. Taratula O, Garbuzenko OB, Kirkpatrick P, et al. Surface-engineered targeted PPI dendrimer for efficient intracellular and intratumoral siRNA delivery. J Control Release 2009;140(3):284-293
86. Hollins AJ, Benboubetra M, Omidi Y, et al. Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor. Pharm Res 2004;21(30):458-466
87. Tack F, Bakker A, Maes S, et al. Modified poly(propylene imine) dendrimers as effective transfection agents for catalytic DNA enzymes (DNAzymes). J Drug Target 2006;14(2):69-86
88. Santhakumaran LM, Thomas T, Thomas TJ. Enhanced cellular uptake of a triplex-forming oligonucleotide by nanoparticle formation in the presence of polypropylenimine dendrimers. Nucleic Acids Res 2004;32(7):2102-2112
89. Zinselmeyer BH, Mackay SP, Schatzlein AG, et al. The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm Res 2002;19(7):960-967
90. Tomalia DA, Reyna LA, Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans 2007;35(Pt 1):61-67
91. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 2009;71(3):445-462
92. Minko T, Patil ML, Zhang M, et al. LHRH-targeted nanoparticles for cancer therapeutics. Methods Mol Biol 2010;624:281-294
93. Kim ID, Lim CM, Kim JB, et al. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain. J Control Release 2010;142(3):422-430
94. Patil ML, Zhang M, Taratula O, et al. Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting. Biomacromolecules 2009;10(2):258-266
95. Han L, Zhang A, Wang H, et al. Tat-BMPs-PAMAM conjugates enhance therapeutic effect of small interference RNA on U251 glioma cells in vitro and in vivo. Hum Gene Ther 2010; In press
96. Waite CL, Roth CM. PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug Chem 2010; In press
97. Hollins AJ, Omidi Y, Benter IF, et al. Toxicogenomics of drug delivery systems: exploiting delivery system-induced changes in target gene expression to enhance siRNA potency. J Drug Targeting 2007;15(1):83-88
98. Yoo H, Sazani P, Juliano RL. PAMAM dendrimers as delivery agents for antisense oligonucleotides. Pharm Res 1999;16(12):1799-1804
99. Kang H, De Long R, Fisher MH, et al. Tat-conjugated PAMAM dendrimers as delivery agents for antisense and siRNA oligonucleotides. Pharm Res 2005;22(12):2099-2106
100. Ustrell V, Hoffman L, Pratt G, et al. PA200, a nuclear proteasome activator involved in DNA repair. Embo J 2002;21:3516-3525
101. May WS, Tyler PG, Ito T, et al. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem 1994;269:26865-26870
102. Ruvolo PP, Deng X, May WS. Phosphorylation of Bcl2 and regulation of apoptosis. Leukemia 2001;15:515-522
103. Dufes C, Keith WN, Bilsland A, et al. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res 2005;65:8079-8084
104. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464(7291):1067-1070